Brightprice6132

Small bowel capsule endoscopy (SBCE) is the gold standard in the study of small bowel bleeding (SBB). Recent studies suggested that longer small bowel transit times (SBTT) may be associated with higher diagnostic yield of SBCE.

The aim of the study is to investigate if longer SBTT is a predictive factor of positive findings on SBCE in a population that performed SBCE due to suspected SBB.

Retrospective single-center study, including consecutive SBCE between May 2012 and May 2019 due to suspected SBB. Positive SBCE was considered in the presence of lesions with high bleeding potential, such as ulcers, angioectasias and tumors (P2 lesions, according to the Saurin classification).

We included 372 patients, 65.9% female, with median age 67 (IQR 19-97) years. We observed that patients with P2 lesions (n=131; 35.2%) in SBCE presented longer SBTT (p=0.01), were older (p<0.001), more frequently male (p=0.019), suffered more frequently from arterial hypertension (p=0.011), diabetes (p=0.042), chronic kidneyant lesions.Background The efficacy and safety after switching to biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD) has been studied, but, few cohort studies compare the pharmacokinetic profiles, immunogenicity and safety of the reference infliximab (IFX) and CPT-13 in real clinical setting. Objective To compare the pharmacokinetic profiles and drug survival on the long-term outcome of reference IFX and CPT-13 at weeks 54 and 104. A secondary objective was to determine the immunogenicity and safety profile on long-term patients with IBD in a real clinical setting. Methods A retrospective observational cohort analysis in a single centre was performed of patients with IBD in treatment with reference IFX or CPT-13. Serum drug concentrations were compared to determine if there were significant differences in pharmacokinetic outcomes between the reference IFX and CPT-13 at 26, 54, 78 and 104 week. The drug survival of reference IFX and CPT-13 was determined at week 54 and 104. Results One hundred and six patients were included during the study period. Forty-five (42.5%) patients received CPT-13 and 61 (57.5%) reference IFX. A total of 347 samples of infliximab serum were analysed, no significant differences were observed between reference IFX and CPT-13. The percentage of patients who achieved serum concentrations in the target therapeutic range was similar in both groups (74.1% reference IFX and 72.5% CPT-13, p= 0.741). At week 54, the withdrawal rates for the reference IFX and CPT-13 were 11.5% and 20.0%, respectively (p=0.226), while at week 104 they were 26.2% and 28.9% (p=0.761). Conclusion In conclusion, the pharmacokinetic characteristics and incidence of immunogenicity of CPT-13, in real clinical setting, are comparable to those of the infliximab originator. The two products also have similar long-term drug survival and the same safety profile.The goal of this research was to assess emergency room frequentation and visit causes, and unscheduled readmissions within the first year after liver transplantation discharge from hospital, as well as their impact on graft and patient survival. This was a retrospective study of the medical records of 98 patients (mean age, 55.6 ± 8.59 years, 77.6 % males) who were consecutively discharged from hospital after receiving a first liver transplant in our institution during the period 2012-2015. All visits to the emergency room during the first year after transplantation were analyzed, and survival at two years after transplantation was calculated. Fifty-six of all 98 patients (57.15 %) visited the emergency room on 117 occasions within the first year post-transplantation. Fever (n = 34; 29.05 %) and digestive symptoms (n = 32; 27.35 %) were the most common causes of consultation, and resulted in over half of visits. Thirty-five of these 56 patients (62.5 %) required urgent readmission during 50 of all 117 (42.7 %) visits, primarily because of infectious complications (44 %) diverse causes (bacterial pneumonia, cholangitis, Clostridium difficile colitis), and biliary tract-related issues. The likelihood of readmission increased from 11.22 % at 30 days after discharge to 22.4 % at 90 days after discharge. Patient survival at 1 and 2 years after transplantation was lower for patients who were readmitted (88.4 % and 80.7 %, respectively) when compared to those who were not (95.56 % and 91.17 %, respectively, p = 0.002).Monocytes play an important role in the pathogenesis of inflammatory bowel disease but data are scarce as a biomarker of activity, above all, in patients under biologic therapies. The aim was to evaluate the value of monocyte measurements in predicting flares in inflammatory bowel disease patients under maintenance treatment with anti-TNF. A prospective, observational cohort study was designed. Relapse was defined as a Harvey-Bradshaw score >4 in Crohn's disease and a partial Mayo score ≥2 in ulcerative colitis. Monocytes concentration was quantified at 4-month intervals for twelve months. 95 consecutive patients were included. The median age was 42 years, 50.5% female and 75% with Crohn's disease. 65 (68.4%) patients remained in clinical remission. Selleck SB225002 Mean monocyte concentration preceding the relapse was 563 (standard deviation 144) compared to 405 (standard deviation 177) in patients who kept in remission. Final monocytes concentration significantly differentiated between relapse and remission in Crohn's disease (AUC 0.82; 95% CI 0.71-0.90; P less then 0.005). In the multivariate analysis, only monocytes and fecal calprotectin related to more relapses. In conclusion, in inflammatory bowel disease patients under anti-TNF therapy, repeated monocytes concentration could help in order to monitoring patients, at least, in Crohn's disease.We report the synthesis of two pyclen-based regioisomer ligands (pyclen = 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene) functionalized with picolinic acid pendant arms either at positions 3,9-pc2pa (L5) or 3,6-pc2pa (L6) of the macrocyclic fragment. The ligands were prepared by the regiospecific protection of one of the amine nitrogen atoms of the macrocycle using Boc and Alloc protecting groups, respectively. The X-ray structure of the Gd(III) complex of L5 contains trinuclear [(GdL5)3(H2O)3]3+ entities in which the monomeric units are joined by μ2-η1η1-carboxylate groups. However, the 1H and 89Y NMR spectra of its Y(III) analogue support the formation of monomeric complexes in solution. The Tb(III) complexes are highly luminescent, with emission quantum yields of up to 28% for [TbL5]+. The luminescence lifetimes recorded in H2O and D2O solutions indicate the presence of a water molecule coordinated to the metal ion, as also evidenced by the 1H relaxivities measured for the Gd(III) analogues. The Gd(III) complexes present very different exchange rates of the coordinated water molecule (kex298 = 87.